Botanix Pharmaceuticals (ASX:BOT) is on track to launch its patient experience program for underarm sweating prescription, Sofdra, in the fourth quarter of the 2024 calendar year, according to a Monday filing with the Australian bourse.
The program intends to introduce Sofdra to its first commercial users for initial feedback before being rolled out to larger volumes of patients in the first quarter of 2025.
The clinical dermatology company added that it is on pace to generate first prescriptions from the sales in the coming months, followed by first refills.
Botanix's shares were up 6% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。